// App-Quantinova.ai

: Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Researchers

Presenter

  • Pooja Shah

Principal Investigators

  • Thorsten Stuehmer

  • Larissa Haertle

  • Daniela Bruennert

  • Umair Munawar

  • Ellen Leich

  • Sabrina Kraus

  • Michael Hudecek

  • Manik Chatterjee

  • Andreas Schlosser

  • Martin Kortuem

  • Ralf C Bargou

  • Hermann Einsele

  • Friederike Berberich-Siebelt

  • Torsten Steinbrunn

Medical Centers

  • Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany

  • Department of Internal Medicine II, University Hospital WüRzburg, W, WüRzburg, DEU

  • Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany

  • HO-CNIO Hematological Malignancies Group, Clinical Research Unit. CNIO, Madrid, Spain

  • Comprehensive Cancer Center Mainfranken, University Hospital of Wuerzburg, Wuerzburg, Germany

  • Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Department of Obstetrics and Gynecology, University Hospital of Wuerzburg, Wuerzburg, Germany

Locations

  • Germany

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • p53

  • Cluster of Differentiation 2AP

  • Regulatory T cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved